Proteomic Analysis of Proteins Eliminated by Low‐Density Lipoprotein Apheresis

Low‐density lipoprotein apheresis (LDL‐A) treatment has been shown to decrease serum LDL cholesterol levels and prevent cardiovascular events in homozygous patients with familial hypercholesterolemia. Recently, LDL‐A treatment has been suggested to have beneficial effects beyond the removal of LDL particles. In this study, to clarify the preventive effects of LDL‐A treatment on atherosclerosis, the waste fluid from the adsorption columns was analyzed. The waste fluid of LDL adsorption columns was analyzed by two‐dimensional electrophoresis followed by mass spectrometry. Serum concentrations of the newly identified proteins before and after LDL‐A treatment were measured by enzyme‐linked immunosorbent assay. We identified 48 kinds of proteins in the waste fluid of LDL adsorption columns, including coagulation factors, thrombogenic factors, complement factors, inflammatory factors and adhesion molecules. In addition to the proteins that were reported to be removed by LDL‐A treatment, we newly identified several proteins that have some significant roles in the development of atherosclerosis, including vitronectin and apolipoprotein C‐III (Apo C‐III). The serum levels of vitronectin and Apo C‐III decreased by 82.4% and 54.8%, respectively, after a single LDL‐A treatment. While Apo C‐III was removed with very low‐density lipoprotein (VLDL) and LDL, vitronectin was removed without association with lipoproteins. The removal of proteins observed in the waste fluid has a certain impact on their serum levels, and this may be related to the efficacy of LDL‐A treatment. Proteomic analysis of the waste fluid of LDL adsorption columns may provide a rational means of assessing the effects of LDL‐A treatment.

[1]  J. O’Connell,et al.  A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection , 2008, Science.

[2]  Melanie Y. White,et al.  The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery* , 2008, Molecular & Cellular Proteomics.

[3]  H. Dihazi,et al.  Protein adsorption during LDL-apheresis: proteomic analysis. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  G. Watts,et al.  Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. , 2008, Clinical science.

[5]  H. Ekmekçi,et al.  Vitronectin in atherosclerotic disease. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[6]  T. Ohtake,et al.  LDL‐Apheresis Reduces P‐Selectin, CRP and Fibrinogen— Possible Important Implications for Improving Atherosclerosis , 2006, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[7]  M. Harada‐Shiba,et al.  Long‐term Effect of Low‐density Lipoprotein Apheresis in Patients with Homozygous Familial Hypercholesterolemia , 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[8]  R. Klingel,et al.  From Membrane Differential Filtration to Lipidfiltration: Technological Progress in Low‐density Lipoprotein Apheresis , 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[9]  W. Fay,et al.  Endogenous Vitronectin and Plasminogen Activator Inhibitor-1 Promote Neointima Formation in Murine Carotid Arteries , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[10]  N. Tani.  Development of selective low-density lipoprotein (LDL) apheresis system: immobilized polyanion as LDL-specific adsorption for LDL apheresis system. , 2000, Artificial organs.

[11]  T. Nishide,et al.  Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). , 1999, Atherosclerosis.

[12]  H. Mabuchi,et al.  Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia , 1998 .

[13]  M. Harada‐Shiba,et al.  Plasma constituents other than low-density lipoprotein adsorbed by dextran-sulfate column. , 1997, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[14]  N. Tani.  Development of selective low-density lipoprotein (LDL) apheresis system: immobilized polyanion as LDL-specific adsorption for LDL apheresis system. 1996. , 1996, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[15]  T. Risler,et al.  Different effects of two methods of low‐density lipoprotein apheresis on the coagulation and fibrinolytic systems 3 , 1993, Journal of internal medicine.

[16]  M. Harada‐Shiba,et al.  Changes in Coagulation Factors by Passage through a Dextran Sulfate Cellulose Column during Low-Density Lipoprotein Apheresis , 1992, The International journal of artificial organs.

[17]  T. Agishi,et al.  Effect of Membrane Trapping in Plasma Fractionator on Separative Characteristics , 1988, The International journal of artificial organs.

[18]  H. Mabuchi,et al.  A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). , 1987, Atherosclerosis.

[19]  P. Malchesky,et al.  Clinical thermofiltration: initial application. , 1985, Artificial organs.

[20]  S. Yokoyama,et al.  Selective Removal of Low Density Lipoprotein by Plasmapheresis in Familial Hypercholesterolemia , 1985, Arteriosclerosis.

[21]  G. Thompson,et al.  PLASMA EXCHANGE IN THE MANAGEMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLÆMIA , 1975, The Lancet.

[22]  R. Touraine,et al.  [Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis ans heroic treatment]. , 1967, Bulletins et memoires de la Societe medicale des hopitaux de Paris.

[23]  P. Ms,et al.  PROTECTION AGAINST RUBELLA , 1965 .

[24]  M. Cucuianu,et al.  Coagulation factor XIII and atherothrombosis. A mini-review. , 2003, Romanian journal of internal medicine = Revue roumaine de medecine interne.

[25]  H. Mabuchi,et al.  Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. , 1998, The American journal of cardiology.

[26]  T. Farag,et al.  Familial hypercholesterolemia. , 1988, Journal of the Royal Society of Medicine.

[27]  P. Malchesky,et al.  Thermal effect of LDL/HDL separation in membrane filtration; thermofiltration. , 1985, Transactions - American Society for Artificial Internal Organs.